This Article Full Text Full Text (PDF) All Versions of this Article: 45/1/120    most recent 01.HYP.0000151323.93372.f5v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by van Esch, J. H.M. Articles by Danser, A.H. J. Search for Related Content PubMed PubMed Citation Articles by van Esch, J. H.M. Articles by Danser, A.H. J. Pubmed/NCBI databases Gene GEO Profiles HomoloGene Protein UniGene Compound via MeSH Substance via MeSH Hazardous Substances DB CAPTOPRIL Related Collections Biochemistry and metabolism ACE/Angiotension receptors Hypertension - basic studies Coronary circulation Endothelium/vascular type/nitric oxide

(Hypertension. 2005;45:120.)
© 2005 American Heart Association, Inc.

Scientific Contributions

Selective Angiotensin-Converting Enzyme C-Domain Inhibition Is Sufficient to Prevent Angiotensin I–Induced Vasoconstriction

Joep H.M. van Esch; Beril Tom; Vincent Dive; Wendy W. Batenburg; Dimitris Georgiadis; Athanasios Yiotakis; Jeanette M.G. van Gool; René J.A. de Bruijn; René de Vries; A.H. Jan Danser

From the Department of Pharmacology (J.H.M.v.E., B.T., W.W.B., R.d.V., A.H.J.D.) and Internal Medicine (J.M.G.v.G., R.J.A.d.B.), Erasmus MC, Rotterdam, The Netherlands; CEA (V.D.), Départment d’Ingénierie et d’Etudes des Protéines, CE-Saclay, France; and Department of Organic Chemistry (D.G., A.Y.), Laboratory of Organic Chemistry, University of Athens, Panepistimiopolis, Zografou, Greece.

Correspondence to Dr A.H.J. Danser, Professor, Department of Pharmacology, Room EE1418b, Erasmus MC, Dr Molewaterplein 50, 3015 GE Rotterdam, The Netherlands. E-mail a.danser{at}erasmusmc.nl

Somatic angiotensin-converting enzyme (ACE) contains 2 domains (C-domain and N-domain) capable of hydrolyzing angiotensin I (Ang I) and bradykinin. Here we investigated the effect of the selective C-domain and N-domain inhibitors RXPA380 and RXP407 on Ang I–induced vasoconstriction of porcine femoral arteries (PFAs) and bradykinin-induced vasodilation of preconstricted porcine coronary microarteries (PCMAs). Ang I concentration-dependently constricted PFAs. RXPA380, at concentrations >1 µmol/L, shifted the Ang I concentration-response curve (CRC) 10-fold to the right. This was comparable to the maximal shift observed with the ACE inhibitors (ACEi) quinaprilat and captopril. RXP407 did not affect Ang I at concentrations 0.1 mmol/L. Bradykinin concentration-dependently relaxed PCMAs. RXPA380 (10 µmol/L) and RXP407 (0.1 mmol/L) potentiated bradykinin, both inducing a leftward shift of the bradykinin CRC that equaled 50% of the maximal shift observed with quinaprilat. Ang I added to blood plasma disappeared with a half life (t_1/2) of 42±3 minutes. Quinaprilat increased the t_1/2 4-fold, indicating that 71±6% of Ang I metabolism was attributable to ACE. RXPA380 (10 µmol/L) and RXP407 (0.1 mmol/L) increased the t_1/2 2-fold, thereby suggesting that both domains contribute to conversion in plasma. In conclusion, tissue Ang I–II conversion depends exclusively on the ACE C-domain, whereas both domains contribute to conversion by soluble ACE and to bradykinin degradation at tissue sites. Because tissue ACE (and not plasma ACE) determines the hypertensive effects of Ang I, these data not only explain why N-domain inhibition does not affect Ang I–induced vasoconstriction in vivo but also why ACEi exert blood pressure–independent effects at low (C-domain–blocking) doses.

Key Words: angiotensin • bradykinin • angiotensin-converting enzyme

This article has been cited by other articles:

				S. Fuchs, H. D. Xiao, C. Hubert, A. Michaud, D. J. Campbell, J. W. Adams, M. R. Capecchi, P. Corvol, and K. E. Bernstein Angiotensin-Converting Enzyme C-Terminal Catalytic Domain Is the Main Site of Angiotensin I Cleavage In Vivo Hypertension, February 1, 2008; 51(2): 267 - 274. [Abstract] [Full Text] [PDF]

				A. H. Jan Danser, W. W. Batenburg, and J. H. M. van Esch Prorenin and the (pro)renin receptor--an update Nephrol. Dial. Transplant., May 1, 2007; 22(5): 1288 - 1292. [Full Text] [PDF]

				S. P. Kessler, P. deS. Senanayake, C. Gaughan, and G. C. Sen Vascular expression of germinal ACE fails to maintain normal blood pressure in ACE-/- mice FASEB J, January 1, 2007; 21(1): 156 - 166. [Abstract] [Full Text] [PDF]

				K. Kohlstedt, C. Gershome, M. Friedrich, W. Muller-Esterl, F. Alhenc-Gelas, R. Busse, and I. Fleming Angiotensin-Converting Enzyme (ACE) Dimerization Is the Initial Step in the ACE Inhibitor-Induced ACE Signaling Cascade in Endothelial Cells Mol. Pharmacol., May 1, 2006; 69(5): 1725 - 1732. [Abstract] [Full Text] [PDF]

				T. L. Reudelhuber A Place in Our Hearts for the Lowly Angiotensin 1-7 Peptide? Hypertension, May 1, 2006; 47(5): 811 - 815. [Full Text] [PDF]

				I. Fleming Signaling by the Angiotensin-Converting Enzyme Circ. Res., April 14, 2006; 98(7): 887 - 896. [Abstract] [Full Text] [PDF]

				K. Kohlstedt, R. Kellner, R. Busse, and I. Fleming Signaling via the Angiotensin-Converting Enzyme Results in the Phosphorylation of the Nonmuscle Myosin Heavy Chain IIA Mol. Pharmacol., January 1, 2006; 69(1): 19 - 26. [Abstract] [Full Text] [PDF]

				W. Chai, I. M. Garrelds, R. de Vries, W. W. Batenburg, J. P. van Kats, and A.H. Jan Danser Nongenomic Effects of Aldosterone in the Human Heart: Interaction With Angiotensin II Hypertension, October 1, 2005; 46(4): 701 - 706. [Abstract] [Full Text] [PDF]